Orforglipron (Oral Non-Peptide GLP-1 Agonist) — Weight & Metabolism
Investigational oral small-molecule GLP-1 receptor agonist in Phase 3, offering daily pill convenience without injections.
Overview
Orforglipron (LY3502970) is a first-in-class oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (Rybelsus), which is a peptide requiring an absorption enhancer (SNAC) and strict fasting requirements, orforglipron is a small molecule with conventional oral bioavailability — it can be taken with or without food. Phase 2 trial results (GZGI study, published NEJM 2023) in adults with obesity demonstrated dose-dependent weight loss up to 14.7% at 36 weeks (highest dose 45 mg daily), comparable to injectable GLP-1 agonists. In type 2 diabetes, orforglipron reduced HbA1c by up to 2.1% and body weight by 10.1%. The drug has a half-life of approximately 29 hours, supporting once-daily dosing. Orforglipron's key advantage is the elimination of injection burden — a major barrier to GLP-1 therapy adherence. Additionally, as a small molecule, manufacturing costs are substantially lower than peptide-based GLP-1 agonists, potentially enabling a price point of $149/month (versus $900-1300+ for injectable GLP-1s). Phase 3 trials (ACHIEVE program) are ongoing for obesity and type 2 diabetes with projected completion in 2025-2026.
Indications
- Investigational: Obesity and overweight (Phase 3)
- Investigational: Type 2 diabetes mellitus (Phase 3)
- Investigational: Cardiovascular outcomes (planned)
Mechanism of Action
Orforglipron is a non-peptide small molecule that binds to and activates the GLP-1 receptor with comparable efficacy to native GLP-1
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Orforglipron | 3 mg | Once daily (starting dose) | Initial titration dose from Phase 2 trials |
| Orforglipron | 36 mg | Once daily | Moderate efficacy dose |
| Orforglipron | 45 mg | Once daily | Highest Phase 2 dose — maximum weight loss |
Evidence Grade
GRADE B
Safety & Contraindications
- Nausea (30-40%), vomiting (10-15%), diarrhea — dose-dependent GI effects
- Decreased appetite (desired therapeutic effect but may be excessive in some)
- GI side effects appear to improve with slow titration and continued use
- No injection site reactions (oral administration)
- Not yet approved — long-term safety profile not established
- Potential for cholelithiasis with rapid weight loss
- Drug-drug interactions not fully characterized